Literature DB >> 1991996

Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms.

G A Watson1, Y X Fu, D M Lopez.   

Abstract

Tumor burden has been shown to induce a variety of phenotypic and functional changes in the cellular constituents of the host's immune system. These changes have been implicated as mechanisms by which tumors avoid rejection. Studies of BALB/c mice bearing a D1-DMBA-3 mammary adenocarcinoma showed alterations of the splenocyte populations. There was a five-fold increase of macrophages (M phi) that were phenotypically and functionally analyzed to establish their role in tumor-induced modifications of the host's immune response. Monoclonal antibody staining defined a Mac-1+2+ population which comprised up to 20% of the splenocytes in tumor-bearers (TB), but is negligible in spleens from normal mice. These Mac-1+2+ M phi were found to mediate down-regulation of both polyclonal and antigen-specific T and B cell responses in vitro and in vivo. Although B cell responses were suppressed via prostaglandin E2 (PGE2) production by the TB M phi, T cell responses were relatively refractory to PGE2-mediated down-regulation. Instead, they were suppressed by a contact-dependent T cell-M phi interaction. Furthermore, tumor-derived factors such as granulocyte-M phi colony-stimulating factor (GM-CSF) seem to play an important role in the induction and expansion of the Mac-1+2+ M phi. These cells appear to mediate down-regulation of the host immune responses by at least two distinct mechanisms: 1) PGE2 production and 2) a cell contact-dependent, but non-major-histocompatibility-complex-specific, interaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991996     DOI: 10.1002/jlb.49.2.126

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  17 in total

Review 1.  Influence of breast cancer on thymic function in mice.

Authors:  Diana M Lopez; Vijaya Charyulu; Becky Adkins
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Insights into thymic involution in tumor-bearing mice.

Authors:  Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 3.  Role of immune-regulatory cells in skin pathology.

Authors:  Dan Ilkovitch
Journal:  J Leukoc Biol       Date:  2010-07-13       Impact factor: 4.962

4.  Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes.

Authors:  M L Jaffe; H Arai; G J Nabel
Journal:  Mol Med       Date:  1996-11       Impact factor: 6.354

5.  Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells.

Authors:  M Pourshafie; Q Ayub; W W Barrow
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

6.  Role of macrophages in the host response to Lewis lung peritoneal carcinomatosis.

Authors:  M W Barth; P S Morahan
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 7.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Authors:  Stefano Ugel; Francesco De Sanctis; Susanna Mandruzzato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

8.  Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.

Authors:  D W Hoskin; T Reynolds; J Blay
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

Review 9.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

Review 10.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.